- Augurex Life Sciences partners with Quest Diagnostics to relaunch the 14-3-3η test in the U.S., addressing growing demand for advanced rheumatoid arthritis diagnostics.
- The partnership expands access to the 14-3-3η test through Quest’s extensive physician network and leading diagnostics infrastructure across the U.S.
Vancouver, Canada – [Date] – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced the relaunch of the 14-3-3η (eta) test in the United States with Quest Diagnostics, the world’s leading provider of laboratory services and diagnostic information services.
The 14-3-3η test provides important insights for early diagnosis, risk assessment, and management of rheumatoid arthritis (RA) by detecting elevated levels of the 14-3-3η protein, which are linked to more severe disease and joint damage risk. In response to increasing demands for advanced diagnostic tools in the early detection and management of RA, healthcare providers will now gain greater access to this diagnostic tool through Quest’s expansive network, enabling timely intervention and improved patient care.
“Reintroducing the 14-3-3η test with Quest Diagnostics is an important step in meeting the evolving needs of RA patients and clinicians,” said Neil Klompas, CEO of Augurex. “With the increasing recognition of 14-3-3η as a valuable biomarker in inflammatory diseases, and in partnership with Quest, this relaunch expands access to an important diagnostic tool which can enable more accurate and timely treatment decisions.”
Quest Diagnostics, with its extensive physician network and robust diagnostics infrastructure, will make the 14-3-3η test widely available to patients and healthcare providers nationwide. This aligns with Augurex and Quest’s shared goals of improving patient outcomes by equipping healthcare providers with clinically validated diagnostic tools to better understand and manage complex autoimmune conditions like RA, and ensuring that patients can benefit from more precise diagnoses and personalized treatment strategies.
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3η protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3η are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. SPINEstat® expands Augurex’s biomarker-informed diagnostic autoimmune portfolio into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.